GlassScriptPhysician profile
Fnu Deepika
NPI 1386166171
$2,040.28
in general payments reported to CMS, 2019-2025
22 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2022: $55.00 · 2023: $409 · 2024: $666 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769 · Education: $63.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.12 |
| Education | $63.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.36 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $236.04 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Amgen INC. | $204.81 | 2023-2025 | Evenity, Prolia, Prolia |
| Alexion Pharmaceuticals, INC. | $146.37 | 2019-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $122.71 | 2023-2025 | |
| Abbott Laboratories | $111.92 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Radius Health, INC. | $90.59 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $71.59 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $63.00 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $62.95 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $55.00 | 2022 | |
| Kyowa Kirin, INC. | $53.92 | 2023-2024 | Crysvita |
| Medtronic, INC. | $49.50 | 2023-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $42.24 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $30.68 | 2024-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $30.29 | 2025 | Rezdiffra |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
| Almatica Pharma LLC | $17.81 | 2024 | Teriparatide |
| Ascensia Diabetes Care US INC. | $17.15 | 2025 | |
| Sequel Med Tech, LLC | $13.65 | 2025 | Twiist |
| Dexcom, INC. | $13.26 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Deepika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.